Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Novartis Pharmaceuticals Corporation

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ligelizumab

            Therapeutic Area: Immunology Product Name: QGE031

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 14, 2021

            Details:

            Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tislelizumab

            Therapeutic Area: Oncology Product Name: BGB-A317

            Highest Development Status: Undisclosed Product Type: Large molecule

            Recipient: BeiGene

            Deal Size: $2,200.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 11, 2021

            Details:

            Novartis Pharma will develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan.